MD970254A - Use of melatonine for treatment of patients having a medicamental dependence - Google Patents

Use of melatonine for treatment of patients having a medicamental dependence

Info

Publication number
MD970254A
MD970254A MD97-0254A MD970254A MD970254A MD 970254 A MD970254 A MD 970254A MD 970254 A MD970254 A MD 970254A MD 970254 A MD970254 A MD 970254A
Authority
MD
Moldova
Prior art keywords
dependence
melatonine
patients
treatment
medicamental
Prior art date
Application number
MD97-0254A
Other languages
Romanian (ro)
Other versions
MD1716C2 (en
MD1716B2 (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of MD970254A publication Critical patent/MD970254A/en
Publication of MD1716B2 publication Critical patent/MD1716B2/en
Publication of MD1716C2 publication Critical patent/MD1716C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to the use of melatonine for treatment of patients having polymedi-camental dependence, patient having symptoms of benzodiasepine drug tolerance or dependence, or patie
MD97-0254A 1995-02-01 1996-01-29 Use of melatonin for treatment of patients dependent on benzodiazepine MD1716C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (3)

Publication Number Publication Date
MD970254A true MD970254A (en) 1999-05-31
MD1716B2 MD1716B2 (en) 2001-08-31
MD1716C2 MD1716C2 (en) 2002-02-28

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
MD97-0254A MD1716C2 (en) 1995-02-01 1996-01-29 Use of melatonin for treatment of patients dependent on benzodiazepine

Country Status (22)

Country Link
JP (1) JP4516159B2 (en)
CN (1) CN1083263C (en)
AT (1) AT408188B (en)
AU (1) AU695366B2 (en)
BG (1) BG62876B1 (en)
BR (1) BR9607169A (en)
CZ (1) CZ291349B6 (en)
DK (1) DK176081B1 (en)
EE (1) EE03384B1 (en)
FI (1) FI119586B (en)
IS (1) IS1980B (en)
LU (1) LU90118B1 (en)
LV (1) LV11940B (en)
MD (1) MD1716C2 (en)
NO (1) NO312814B1 (en)
NZ (1) NZ298878A (en)
PL (1) PL183148B1 (en)
SI (1) SI9620022A (en)
SK (1) SK284521B6 (en)
TR (1) TR199700723T1 (en)
TW (1) TW483757B (en)
WO (1) WO1996023496A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287508B6 (en) 2000-01-05 2010-12-07 Neurim Pharmaceuticals (1991) Ltd. Use and formulation for treating resistance to antihypertensives and related conditions
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
KR20180100450A (en) 2012-01-26 2018-09-10 반다 파마슈티칼즈, 인코퍼레이티드. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR102148990B1 (en) 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. Treatment of circadian rhythm disorders
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
SI3337462T1 (en) * 2016-10-31 2021-01-29 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518468B1 (en) * 1991-05-09 1999-06-30 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions
IT1251544B (en) * 1991-05-13 1995-05-17 Gabriele Biella PHARMACEUTICAL COMPOSITIONS ACTIVE IN THE THERAPY OF SLEEP DISORDERS INCLUDING MELATONIN OR A DERIVATIVE IN ASSOCIATION WITH A BENZODIAZEPINE DERIVATIVE

Also Published As

Publication number Publication date
CN1172431A (en) 1998-02-04
JPH10513177A (en) 1998-12-15
CZ291349B6 (en) 2003-02-12
IS4532A (en) 1997-07-25
BG62876B1 (en) 2000-10-31
AU695366B2 (en) 1998-08-13
WO1996023496A1 (en) 1996-08-08
TR199700723T1 (en) 1998-02-21
TW483757B (en) 2002-04-21
SK103097A3 (en) 1998-01-14
DK89697A (en) 1997-07-30
CN1083263C (en) 2002-04-24
NO973531L (en) 1997-09-30
MX9705856A (en) 1998-07-31
MD1716C2 (en) 2002-02-28
PL183148B1 (en) 2002-05-31
AT408188B (en) 2001-09-25
FI973185A (en) 1997-09-30
IS1980B (en) 2005-01-14
NO312814B1 (en) 2002-07-08
DK176081B1 (en) 2006-04-18
LV11940A (en) 1998-01-20
SI9620022A (en) 1998-10-31
FI973185A0 (en) 1997-07-31
NZ298878A (en) 1999-05-28
ATA901396A (en) 2001-02-15
SK284521B6 (en) 2005-05-05
BG101803A (en) 1998-04-30
LV11940B (en) 1998-05-20
EE9700166A (en) 1998-02-16
MD1716B2 (en) 2001-08-31
AU4457496A (en) 1996-08-21
EE03384B1 (en) 2001-04-16
BR9607169A (en) 1997-11-11
NO973531D0 (en) 1997-07-31
LU90118B1 (en) 1997-11-13
PL321630A1 (en) 1997-12-08
CZ240597A3 (en) 1998-01-14
JP4516159B2 (en) 2010-08-04
FI119586B (en) 2009-01-15

Similar Documents

Publication Publication Date Title
HUP9700603A1 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
ES2165910T3 (en) NASAL AND OCULAR CETAMINE ADMINISTRATION FOR THE TREATMENT OF PAIN AND FOR DETOXIFICATION.
BG101118A (en) Therapeutical compounds
NO20101190L (en) Use of buprenorphine in the manufacture of a medicament
IL127714A0 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic depressive bipolar disorders
AU677279B2 (en) Application of carbamazepine and oxcarbazepine in the treatment of Parkinson's disease and Parkinsonian syndromes
HUT77927A (en) Use of nebivolol for producing anti-atherogenic pharmaceuticals and combination pharmaceuticals containing them
PT998287E (en) USES OF LEVOBUPIVACAINE
AU4024797A (en) Use of arachidonic acid and/or docosahexanoic acid for the manufacture of a medicament for the treatment of dyspraxia
HUP0001014A2 (en) Use of gastrointestinal lipase inhibitors
ES2160643T3 (en) COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF.
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
GB0020504D0 (en) Therapeutic method
AU2001261987A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
AU2787495A (en) Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
MX9803610A (en) Use of flupirtin for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system.
IT1288399B1 (en) MEDICATION FOR THE THERAPEUTIC TREATMENT OF AGE-RELATED MACULOPATHY, NON-AGE-RELATED MACULOPATHY AND FOR PROPHYLAXIS
NO990450L (en) Treatment of mental disorders
AU7718796A (en) 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
NO984651L (en) Use of benzone-offset derivatives for the manufacture of drugs for the treatment of central nervous system diseases
AU5434899A (en) Cancer treatment
AU5890499A (en) Use of composition in the treatment of schizophrenia
UA22223A (en) Method for treatment of vision organ diseases
UA30361A (en) The method for treatment of glycoside intoxication

Legal Events

Date Code Title Description
PD99 Pending application
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees